Weekly Investment Analysts’ Ratings Changes for Astrazeneca (AZN)

Astrazeneca (NYSE: AZN) recently received a number of ratings updates from brokerages and research firms:

• 3/20/2026 – Astrazeneca was upgraded by Wall Street Zen from “hold” to “buy”.
• 3/18/2026 – Astrazeneca had its “buy” rating reaffirmed by TD Cowen.
• 3/12/2026 – Astrazeneca was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/11/2026 – Astrazeneca is now covered by Weiss Ratings. They set a “buy (b)” rating on the stock.
• 2/6/2026 – Astrazeneca had its “sell” rating reaffirmed by Deutsche Bank Aktiengesellschaft.
• 1/27/2026 – Astrazeneca is now covered by Citigroup Inc.. They set a “buy” rating on the stock.

Astrazeneca Dividend Announcement

The company also recently declared a dividend, which was paid on Monday, March 23rd. Stockholders of record on Friday, February 20th were issued a $1.595 dividend. This represents a dividend yield of 156.0%. The ex-dividend date of this dividend was Friday, February 20th. Astrazeneca’s dividend payout ratio is presently 74.83%.

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.